Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of the combination therapy
with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in
patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical
resection or percutaneous ablation therapy.